2016;9:e004370. S7.9.1.1-7. Chorin E, Taub R, Medina A, et al. Long-term flecainide therapy in type 3 long QT syndrome. Europace. 2017 euw439 [Epub ahead of print]. S7.9.1.1-8. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA. 2006;296:1249 54. S7.9.1.1-9. Jons C, Moss AJ, Goldenberg I, et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol. 2010;55:783 8. S7.9.1.1-10. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67:1053 8. S7.9.1.1-11. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inherited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183 9. S7.9.1.1-12. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolonga- tion and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr. 2009;168:1107 15. CLINICAL STATEMENTS AND GUIDELINES S7.9.1.1-13. Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and cate- cholaminergic polymorphic ventricular tachycardia using video- assisted thoracic surgery. Heart Rhythm. 2009;6:752 9. S7.9.1.1-14. Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic sympathectomy for cardiac denervation in patients with life- threatening ventricular arrhythmias. J Thorac Cardiovasc Surg. 2014;147:404 9. S7.9.1.1-15. Schneider HE, Steinmetz M, Krause U, et al. Left cardiac sym- pathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catechol- aminergic polymorphic ventricular tachycardia and long QT syn- drome. Clin Res Cardiol. 2013;102:33 42. S7.9.1.1-16. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109:1826 33. S7.9.1.1-17. 